2023
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials
Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, Ambrose C, Hellqvist Å, Roseti S, Molfino N, Llanos J, Martin N, Bowen K, Griffiths J, Parnes J, Colice G. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. American Journal Of Respiratory And Critical Care Medicine 2023, 208: 13-24. PMID: 37015033, PMCID: PMC10870853, DOI: 10.1164/rccm.202210-2005oc.Peer-Reviewed Original ResearchConceptsAsthma exacerbation rateUncontrolled asthmaExacerbation rateSecondary outcomesClinical trialsOverall populationRelevant subgroupsMeaningful reductionEfficacy of tezepelumabExacerbation-related hospitalizationsSafety of tezepelumabPlacebo-controlled trialEmergency department visitsInflammatory biomarker levelsNitric oxide levelsAdverse eventsAllergy statusBaseline bloodClinical characteristicsDepartment visitsPooled analysisNAVIGATOR trialBiomarker levelsOxide levelsTezepelumab
2009
Intensive Care Unit Management of Status Asthmaticus
Marshall P, Possick J, Chupp G. Intensive Care Unit Management of Status Asthmaticus. Clinical Pulmonary Medicine 2009, 16: 293-301. DOI: 10.1097/cpm.0b013e3181bdff38.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSevere asthma exacerbationsNear-fatal asthmaStatus asthmaticusMechanical ventilationAsthma exacerbationsExtrinsic positive end-expiratory pressureIntensive care unit managementPositive end-expiratory pressureEmergency department visitsNoninvasive mechanical ventilationSubset of patientsEnd-expiratory pressureTypical risk factorsHigh-risk populationRisk of barotraumaUse of sedativesSevere exacerbationsICU admissionSevere asthmaPermissive hypercapniaSystemic therapyDepartment visitsHospital admissionExpiratory pressureRisk stratification